Bli medlem
Bli medlem

Du är här

2016-05-12

Ablynx: ABLYNX REPORTS FINANCIAL RESULTS FOR THE FIRST THREE MONTHS OF 2016 AND PROVIDES BUSINESS UPDATE YEAR-TO-DATE

REGULATED INFORMATION

* Reported positive top line results from first-in-infant Phase I/IIa study
of the inhaled anti-RSV Nanobody® (ALX-0171)
* Clinical product pipeline expanded with the initiation of three Phase I
studies in partnered programmes - eight Nanobodies are now in clinical
development
* Early-stage product pipeline significantly expanded with the start of 10
new programmes
* On-track for first potential launch of caplacizumab (anti-vWF for the
treatment of acquired TTP) in 2018
* Important catalysts expected before year-end

GHENT, Belgium, 12 May 2016 -
Ablynx[Euronext Brussels: ABLX; OTC: ABYLY]

today announced its non-audited financial position for the first three months
of 2016, a business update for the year so far and the outlook for the next
period.

Business highlights year-to-date

* Met primary endpoint of safety and tolerability for the inhaled anti-RSV
Nanobody (ALX-0171) in a Phase I/IIa study in infants, aged 1-24 months,
hospitalised with an RSV infection. In addition, inhaled ALX-0171 had an
immediate impact on viral replication and also reduced viral load, as
compared to placebo. There was also an encouraging initial indication of
therapeutic effect. These results support the advancement of the programme
into a Phase II efficacy study in infants in Q4 2016.
* Ablynx's partner, Boehringer Ingelheim started two Phase I trials with
Nanobodies triggering milestone payments to Ablynx totalling €16 million.
The first trial is with a bi-specific anti-VEGF/Ang2 Nanobody, BI 836880,
in patients with solid tumours. The second trial is with an anti-CX3CR1
Nanobody, BI 655088, in healthy volunteers - the initial target indication
for this Nanobody will be chronic kidney disease.
* Ablynx's partner, Novartis received clearance by the FDA to start a Phase I
study with a Nanobody that binds to a GPCR target, which triggered an
undisclosed payment to Ablynx.
* Publication inThe New England Journal of Medicine of the TITAN Phase II
study of the wholly-owned anti-vWF Nanobody, caplacizumab, in patients with
acquired TTP. Continued progress in recruitment for the Phase III HERCULES
study with caplacizumab and preparations are underway to file for
conditional approval in Europe in H1 2017.
* On-track to communicate top line results in Q3 2016 from the Phase IIb RA
monotherapy and combination therapy studies of the anti-IL-6R Nanobody,
ALX-0061, partnered with AbbVie. Patients from both studies have continued
to roll-over into the open-label extension study. Recruitment for the Phase
II STEADY study of ALX-0061 in patients with moderate to severe active SLE
continues to proceed well, with the goal to communicate initial results in
2018.
* Initiated 10 pre-clinical proprietary and partnered programmes with now
more than 40 programmes in the pipeline, of which 8 are in clinical
development.

Financial highlights - first quarter 2016

* Revenues up 94% to €27.4 million (2015: €14.1 million)
* Investment in R&D up 49% to €24.9 million (2015: €16.7 million)
* Operating result of -€0.7 million (2015: -€5.0 million)
* Net cash outflow of €2.5 million (2015: €12.9 million)
* €233.7 million in cash, cash equivalents, restricted cash and short-term
investments (2015: €193.3 million)

Commenting on today's update, Dr Edwin Moses, CEO of Ablynx, said:

"We are very pleased to report excellent progress since the beginning of the
year. Our clinical product pipeline is rapidly expanding with eight
programmes now in clinical development, of which two are bi-specific
Nanobodies, two are Nanobodies against GPCRs and one is an inhaled product,
demonstrating the broad potential of our platform to generate innovative
therapeutics. With the positive outcome of the Phase I/IIa study of our
wholly-owned inhaled anti-RSV Nanobody, ALX-0171, we have made an important
step forward in the development of a possible breakthrough for the treatment
of RSV infections in infants. This trial also illustrates the potential to
use inhalation as the route of administration in the development of
Nanobodies for the treatment of other important lung-based diseases."

"We look forward to continuing important developments throughout 2016."

Financial review

----------------------------------------------------------------------------------------------
| (€ million) First three months 2016 First three months 2015 % change |
| Total revenue and grant income 27.4 14.1 94% |
| R&D income 27.2 13.9 96% |
| Grants 0.2 0.2 - |
| Operating expenses (28.1) (19.1) 47% |
| R&D (24.9) (16.7) 49% |
| G&A (3.2) (2.5) 28% |
| Operating result (0.7) (5.0) 86% |
| Net financial result 17.5 1.1 >100% |
| Net result 16.8 (4.0) >100% |
| Net cash flow (2.5) (12.9) 81% |
| Cash at 31 March 233.7(1) 193.3(2) 21% |
----------------------------------------------------------------------------------------------
(1) including €1.3 million in restricted cash

(2) Including €2.0 million restricted cash

Revenues increased 94% to €27.4 million (2015: €14.1 million) mainly driven by
higher milestones and recognition of upfront payments from on-going
collaborations. As a result of the pipeline maturing with later-stage
clinical assets, the operating expenses increased to €28.1 million (2015:
€19.1 million) primarily due to higher external R&D costs. The net financial
result increased to €17.5 million (2015: €1.1 million) mainly relating to the
effect of the fair value calculation of the Convertible Bond. As a result of
the above, the Company ended the period with a net profit of €16.8 million
(2015: net loss of €4.0 million).

As of 31stMarch 2016, the Company had €233.7 million in cash, cash
equivalents, restricted cash and short-term investments.

Financial guidance and 2016 outlook confirmed

In the third quarter of 2016, Ablynx expects to communicate top line results
from the monotherapy and combination therapy studies with the anti-IL-6R
Nanobody, ALX-0061, in patients with RA. Following a review of the complete
RA data package, AbbVie is expected to decide, before the end of 2016,
whether it intends to exercise its option to exclusively license ALX-0061 in
RA, in which case Ablynx will receive a US$75 million milestone payment.
AbbVie would then be responsible for providing all the resources to further
develop and commercialise ALX-0061 in this indication and Ablynx would be
eligible to receive regulatory and sales milestones plus double-digit
royalties.

In the third quarter of 2016, the Company expects that the first patients from
the Phase III HERCULES study of its wholly-owned anti-vWF Nanobody,
caplacizumab, will have rolled-over into a three-year follow-up study to
evaluate the long-term safety and clinical effects of the product.
In the fourth quarter 2016, Ablynx expects to start a Phase II efficacy study
with the wholly-owned inhaled anti-RSV Nanobody, ALX-0171, in infants who are
hospitalised as a result of an RSV infection.

The Company reiterates its net cash burn guidance for the full year 2016 of
€65-75 million.

Financial calendar 2016

25 August 2016 - half-year results
23 November 2016 - Q3 results

Shareholders' clubs @ Ablynx

18 May at 5.45pm - in Dutch
14 September at 5.45pm - in Dutch
7 December at 5.45pm - in Dutch

If you would like to attend, please contact us viainvestors@ablynx.com.

Glossary

FDA U.S. Food and Drug Administration
GPCR G-protein coupled receptor
IL-6R receptor of interleukin-6
RA rheumatoid arthritis
RSV respiratory syncytial virus
SLE systemic lupus erythematosus
TTP thrombotic thrombocytopenic purpura

About Ablynx

Ablynxis a biopharmaceutical company engaged in the development ofNanobodies®,
proprietary therapeutic proteins based on single-domain antibody fragments,
which combine the advantages of conventional antibody drugs with some of the
features of small-molecule drugs. Ablynx is dedicated to creating new
medicines which will make a real difference to society. Today, the Company
has more than40 proprietary and partnered programmesin development in various
therapeutic areas including inflammation, haematology, immuno-oncology,
oncology and respiratory disease. The Company has collaborations with
multiple pharmaceutical companies including AbbVie, Boehringer Ingelheim,
Eddingpharm, Genzyme, Merck&Co., Inc., Merck KGaA, Novartis, Novo Nordisk and
Taisho Pharmaceuticals. The Company is headquartered in Ghent, Belgium. More
information can be found onwww.ablynx.com.

For more information, please contact

Ablynx:

Dr Edwin Moses
CEO
t: +32 (0)9 262 00 07
m: +32 (0)473 39 50 68
e: edwin.moses@ablynx.com

Marieke Vermeersch
Associate Director Investor Relations
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e: marieke.vermeersch@ablynx.com

Follow us on Twitter @AblynxABLX

Ablynx media relations

FTI Consulting:

Julia Phillips, Brett Pollard, Mo Noonan, Matthew Moss
t: +44 20 3727 1000
e: ablynx@fticonsulting.com

pdf format of the press release
http://hugin.info/137912/R/2011870/745003.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Ablynx via Globenewswire

HUG#2011870

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.